Efficacy, safety and tolerance of imidocarb dipropionate versus atovaquone or buparvaquone plus azithromycin used to treat sick dogs naturally infected with the Babesia microti-like piroplasm

[1]  A. Estrada-Peña,et al.  A review of canine babesiosis: the European perspective , 2016, Parasites & Vectors.

[2]  Shanker K. Singh,et al.  Control and therapeutic management of bovine tropical theileriosis in crossbred cattle , 2016, Journal of Parasitic Diseases.

[3]  Joachim Müller,et al.  Repurposing of antiparasitic drugs: the hydroxy-naphthoquinone buparvaquone inhibits vertical transmission in the pregnant neosporosis mouse model , 2016, Veterinary Research.

[4]  E. Innes,et al.  Detection of Babesia annae DNA in lung exudate samples from Red foxes (Vulpes vulpes) in Great Britain , 2016, Parasites & Vectors.

[5]  S. Wahid,et al.  In-vitro sensitivity of Pakistani Leishmania tropica field isolate against buparvaquone in comparison to standard anti-leishmanial drugs. , 2015, Experimental parasitology.

[6]  Alexander W. Gofton,et al.  Theileria annae (syn. Babesia microti-like) infection in dogs in NW Spain detected using direct and indirect diagnostic techniques: clinical report of 75 cases , 2015, Parasites & Vectors.

[7]  M. Florin-Christensen,et al.  Reclassification of Theileria annae as Babesia vulpes sp. nov. , 2015, Parasites & Vectors.

[8]  Joachim Müller,et al.  Buparvaquone is active against Neospora caninum in vitro and in experimentally infected mice , 2015, International journal for parasitology. Drugs and drug resistance.

[9]  F. Bolás-Fernández,et al.  Unresponsiveness of Experimental Canine Leishmaniosis to a New Amphotericin B Formulation , 2015 .

[10]  X. Roura,et al.  Seropositivity rates for agents of canine vector-borne diseases in Spain: a multicentre study , 2013, Parasites & Vectors.

[11]  A. Birkenheuer,et al.  Re-emergence of Babesia conradae and effective treatment of infected dogs with atovaquone and azithromycin. , 2012, Veterinary parasitology.

[12]  F. Clubb,et al.  Resolution of a proteinuric nephropathy associated with Babesia gibsoni infection in a dog. , 2011, Journal of the American Animal Hospital Association.

[13]  I. Cruz,et al.  Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. , 2009, Veterinary dermatology.

[14]  R. Jefferies,et al.  PCR-RFLP for the detection and differentiation of the canine piroplasm species and its use with filter paper-based technologies. , 2007, Veterinary parasitology.

[15]  Angel García.  Piroplasma infection in dogs in northern Spain. , 2006, Veterinary parasitology.

[16]  H. Vial,et al.  Chemotherapy against babesiosis. , 2006, Veterinary parasitology.

[17]  E. Breitschwerdt,et al.  Efficacy of combined atovaquone and azithromycin for therapy of chronic Babesia gibsoni (Asian genotype) infections in dogs. , 2004, Journal of veterinary internal medicine.

[18]  S. Telford,et al.  Azotemia and mortality among Babesia microti-like infected dogs. , 2004, Journal of veterinary internal medicine.

[19]  A. Gupta,et al.  In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys. , 2003, The Journal of veterinary medical science.

[20]  S. Telford,et al.  Case-control study of canine infection by a newly recognised Babesia microti-like piroplasm. , 2003, Preventive veterinary medicine.

[21]  A. Criado-Fornelio,et al.  Molecular studies on Babesia, Theileria and Hepatozoon in southern Europe. Part II. Phylogenetic analysis and evolutionary history. , 2003, Veterinary parasitology.

[22]  A. Criado-Fornelio,et al.  Molecular studies on Babesia, Theileria and Hepatozoon in southern Europe. Part I. Epizootiological aspects. , 2003, Veterinary parasitology.

[23]  A. Baggish,et al.  Antiparasitic Agent Atovaquone , 2002, Antimicrobial Agents and Chemotherapy.

[24]  S. Telford,et al.  Infection of dogs in north-west Spain with a Babesia microti-like agent , 2001, Veterinary Record.

[25]  K. Fujisaki,et al.  Development of a polymerase chain reaction method for diagnosing Babesia gibsoni infection in dogs. , 2001, The Journal of veterinary medical science.

[26]  S. Telford,et al.  Atovaquone and azithromycin for the treatment of babesiosis. , 2000, The New England journal of medicine.

[27]  Joanne M. Morrisey,et al.  Resistance mutations reveal the atovaquone‐binding domain of cytochrome b in malaria parasites , 1999, Molecular microbiology.

[28]  J. Gray,et al.  Therapeutic efficacy of atovaquone against the bovine intraerythrocytic parasite, Babesia divergens. , 1997, The Journal of parasitology.

[29]  L. Weiss,et al.  Atovaquone in the treatment of Babesia microti infections in hamsters. , 1996, The American journal of tropical medicine and hygiene.

[30]  V. M. Lane,et al.  Efficacy of buparvaquone as a therapeutic and clearing agent of Babesia equi of European origin in horses. , 1992, American journal of veterinary research.

[31]  A. Hudson,et al.  Antitheilerial activity of BW720C (buparvaquone): a comparison with parvaquone. , 1985, Research in veterinary science.

[32]  R. Williams,et al.  Novel anti-malarial hydroxynaphthoquinones with potent broad spectrum anti-protozoal activity , 1985, Parasitology.

[33]  A. Birkenheuer,et al.  Efficacy of atovaquone and azithromycin or imidocarb dipropionate in cats with acute cytauxzoonosis. , 2011, Journal of veterinary internal medicine.

[34]  A. L. Boozer,et al.  Canine babesiosis. , 2003, The Veterinary clinics of North America. Small animal practice.